CO 2 atmosphere. After incubation for 72 h, the medium in each well was replaced with fresh medium and the cells were incubated for another 24 h.
The medium in the wells was then removed and the cells were washed with fresh conditioned medium to remove any released insulin. Next, 360 ml of conditioned medium, with or without 20 ml of glucose solution (20 mg/ml; 16.7 mM vs. 11.1 mM final concentration, respectively) and 20 ml of the test compound solution at various concentrations (20 mM-20 mM) were pipetted into the wells, except for the blank and no-drug controls. After 3 h incubation, aliquots of medium in all wells were withdrawn and centrifuged to remove the cells. The concentration of insulin in the supernatants was determined using the EIA system. The absorbance at 490 nm was measured using a microplate reader. The activities of the compounds tested were evaluated by the increase in concentration of released insulin compared with the high-glucose control in the absence of test compounds. Each experiment was done in triplicate, and the results are presented as meansϮS.D. Groups of data were compared using Student's t-test.
Assay of Cytotoxicity Cytotoxicity was determined by the CellTiter 96 ® AQ ueous One Solution Cell Proliferation Assay. Cells at a concentration of 2.0ϫ10 4 cells/well in 96well plates were inoculated and incubated with conditioned RPMI 1640 medium at 37°C under a 5% CO 2 atmosphere. After incubation for 72 h, the RIN-5F cells were treated with or without active (i.e., A or B series) compounds for 24 h, then 20 ml of the CellTiter 96 ® AQ ueous One Solution Cell Proliferation Assay solution was pipetted into all 96 wells and the cells were further incubated for 1 h. The absorbance at 490 nm was measured using a microplate reader.
RESULTS AND DISCUSSION
We investigated the stimulatory activities of the above compounds on insulin secretion in vitro in order to estimate their anti-diabetic potential. A rat insulin enzyme-immunoassay system is commercially available for evaluation of in vitro activities. Activities were estimated from the concentration of insulin released from pancreatic RIN-5F cells into the medium by adding two series (A and B) of test compounds. The results are shown in Fig. 1 . No-drug (negative) control and high-glucose (HG) control wells without added test compounds were included in each experiment. As a positive control, we used glybenclamide, an established anti-diabetic agent known to stimulate pancreatic cells and cause insulin secretion. As shown in Fig. 1A , compounds A, A1, A4 and A5 elicited significant insulin secretion at a concentration of 100 mM in comparison with the HG control. In particular, compound A exhibited almost 10 times higher insulin secretion than the HG control. The activity of compound A is comparable to that of Glybenclamide. In contrast, compounds A2, A3 and A6 showed no significant activity. In Fig.  1B , compounds B2, B4 and B5 stimulated significant insulin secretion at a concentration of 100 mM, with compound B5 exhibiting almost 9 times higher insulin secretion than the HG control. Compounds B, B1, B3 and B6 showed no significant activity. The opposite profile of activities between unseparated compounds (A or B) and separated compounds (A1, A5 for A series and B4, B5 for B series) was observed.
The reason for the different profile is presently unknown, and the mechanism of insulin release remains to be explored.
Next, we performed dose-response experiments using glybenclamide and the statistically significant ( pϽ0.01) active compounds (A, A1, A5, B4 and B5) shown in Figs. 1A and   922 Vol. 31, No. 5 B. The dose-response curves are shown in Fig. 2 . All compounds tested showed simple sigmoidal dose-response curves, suggesting a single mechanism for each agent. The concentrations at 50% efficacy (ED 50 ) were similar, around 50 mM, suggesting that their affinities for an assumed receptor are almost the same. Since their maximal activities are different, their efficacy characteristics such as agonist, partial agonist or antagonist would be different, indicating the necessity for further investigation.
Toxicity profiles of significantly potent compounds including glybenclamide in the cell cultures were determined from 1 to 1000 mM by the CellTiter 96 ® AQ ueous One Solution Cell Proliferation Assay. Compounds tested did not show apparent cytotoxicity up to 100 mM (Fig. 3) . In contrast, it seemed that glybenclamide was more toxic than the compounds prepared from algae. Cell proliferation during the 3-h incubation period of the insulin secretion assay was insufficient for detecting cytotoxicity, (e.g., inhibition of cell growth), therefore, the cultures were incubated for 24 h with the compounds to test for cytotoxicity. Since the insulin secretion assay is a 3-h test whereas the toxicity assay is conducted after 24-h, the toxicity profile in the toxicity assay is exaggerated compared with the presumed toxicity in the insulin secretion assay. Therefore, the activities of compounds prepared from the algae were not due to their toxicity.
It is known that insulin secretion from pancreatic b cells is stimulated by SUs, and the mechanisms by which insulin is released by these drugs have been elucidated. SUs bind to SU receptors, causing closure of ATP sensitive K ϩ channels in the pancreatic b cell plasma membrane which results in membrane depolarization, calcium influx, and insulin secretion. 10) In addition, SUs act by direct interaction with the secretory machinery. 10) Although the precise mechanisms of SU action are not clear, islet amyloid polypeptide (IAPP, amylin) inhibits insulin secretion by glybenclamide. 5, 6, 11) In this paper, two potent compounds in series A and B, namely compounds A and B5, stimulated insulin secretion as much as the SU, glybenclamide. Amylin had no influence on the insulin secretion effects of compounds prepared from algae on RIN-5F cells ( Fig. 4 ), suggesting that the stimulatory effects of glybenclamide and the compounds tested arise from different mechanisms.
The stimulatory effects of selected test compounds together with glybenclamide were also investigated. As shown in Fig. 5 , the effect of the combination of 50 mM A and 50 mM glybenclamide was almost the same as the effect of 50 mM A plus the effect of 50 mM glybenclamide; the effect of the combination of 50 mM B5 and 50 mM glybenclamide was also almost the same as the effect of 50 mM B5 plus the effect of 50 mM glybenclamide. Although the results per se suggest an additive effect of these drugs, the results do not suggest any mechanism for the activity of the compounds tested.
Collectively, the compounds extracted from algae used in this study have stimulatory activities on insulin secretion by RIN-5F cells (the RIN-m rat islet cell line), comparable to the activity of glybenclamide, a typical SU drug. However, the mechanism(s) of the activity of these compounds appears to be different from that of glybenclamide.
Physiological insulin secretion would been regulated by many intrinsic factors such as free fatty acids, amino acids and newly identified hormones (GLP-1; glucagon-like polypeptide-1, PACAP; pituitary adenylate cyclase activating polypeptide, and others). Intracellular signal transduction including K ATP channel dependent and independent mechanisms, and extracellular CaR (calcium-sensing receptor) The concentration of all test compounds was 100 mM. Significant differences between two parallel groups (with amylin and without amylin), * pϽ0.05. Fig. 5 . The Effect of the Combination of Select Test Compounds and Glybenclamide on Insulin Secretion by RIN-5F Cells mechanism including MAPK (mitogen-activated protein kinase) cascade for insulin secretion has been recently elucidated. Insulin secretion is also regulated by exocytosis mechanism depending on several molecules. Therefore, polysaccharide compounds prepared from algae could have one or number of mechanisms mentioned above. Ganoder lucidum polysaccharide, however, is reported to have insulin-releasing effect through Ca 2ϩ influx into pancreatic b cells, 12) which suggests that compounds extracted from algae reported here may have a similar mechanism to that of Ganoderma lucidum polysaccharide.
Since in vivo pancreatic b cells might be different from the RIN-5F cell line in terms of insulin secretion mechanisms, and thus may respond differently to these compounds, experiments using other insulin-producing cell lines and primary culture b cells would provide additional insights. Moreover, a compound could have multiple in vitro and in vivo activities on pathological conditions such as hyperlipidemia and/or atherosclerosis. 4, 13) Some natural ingredients of herbal medicines have several biological activities in common; likewise, the compounds tested in this study could have several activities. Systems using different types of cells (e.g., vascular endothelium) and animal in vivo experiments are necessary for determining other anti-diabetic activities.
NIDDM is an intricate chronic disease that may require a multi-pronged approach for its control, such as diet, exercise and multi-faceted drugs. Therefore, the compounds investigated in this study are potentially useful as anti-diabetic drugs, but further studies aimed at drug development are required.
CONCLUSION
In this paper, we described the stimulatory effects of two series of compounds derived from algae extracts on in vitro insulin secretion by rat pancreatic RIN-5F cells. Several compounds significantly promoted insulin-release, in particular compounds A and B5. Therefore, effective biological agents can be obtained from natural compounds, especially marine organisms, and their efficacy in vivo, and well as their mechanism of action, should be studied further.
